Healthcare Business

FDA_logo

10 Major Pharma and FDA Catalysts Coming in December

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
blue eye

EyeGate Pharmaceuticals Continues to Win in Mid-Stage Trial

EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) shares rose about 10% on Monday after the company announced promising data from its mid-stage trial of its leading product candidate. Specifically, the data came ...
Read Full Story »
Jon's friends

NeuroDerm Jumps on Critical FDA Update

NeuroDerm Ltd. (NASDAQ: NDRM) shares surged in Monday’s session following a critical update from the U.S. Food and Drug Administration (FDA). The company announced that after its End-of-Phase 2 meeting with ...
Read Full Story »
Marijuana background leaf

GW Pharmaceuticals Shows Smaller Than Expected Q4 Loss

GW Pharmaceuticals PLC (NASDAQ: GWPH) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The company posted a net loss of $0.89 per share and $2.2 million ...
Read Full Story »
Unhealthy Person

Cempra Rises on Late-Stage Trial

Shares of Cempra Inc. (NASDAQ: CEMP) saw a handy gain early on Monday after Toyama Chemical announced that it had begun Phase 3 clinical trials with solithromycin in Japan for patients ...
Read Full Story »
Doctor, Health (pulse) copy

4 Merrill Lynch Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential

One thing that many on Wall Street felt was hampering the pharmaceutical and medical technology stocks was the potential for a Hillary Clinton victory last month. Her harsh rhetoric on drug ...
Read Full Story »
hospital entrance

Envision Healthcare Triples on Completed Merger

Shares of Envision Healthcare Holdings Inc. (NYSE: EVHC) more than tripled in Friday’s session after the company announced the completion of its merger with Amsurg. These health care companies are ...
Read Full Story »
Female patient on gurney

Recro Pharma Files for Secondary Offering Following Big Late-Stage Win

Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced a secondary offering. No pricing details were given in the filing, but the offering is ...
Read Full Story »
Medicine pills

Analyst’s Top Pharmaceutical Buys Offer Big Dividends and Growth Potential

Ever since the fall of last year when Hillary Clinton spoke out on high drug prices, the top stocks in the pharmaceutical sector have taken a beating. With Clinton defeated ...
Read Full Story »
IPO

TiGenix Closes in on IPO

TiGenix has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company did not give any pricing details in ...
Read Full Story »
blue eye

Clearside Biomedical Gears Up for Secondary Offering

Clearside Biomedical Inc. (NASDAQ: CLSD) has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The company did not give any pricing ...
Read Full Story »
FDA_logo

FDA Requests Additional Data on Amicus’ Fabry Disease Treatment

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company ...
Read Full Story »
burning cash

Nivalis Therapeutics Crumbles on Failed Mid-Stage Trial

Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline ...
Read Full Story »
doctor

Genetic Technologies Practically Doubles on Licensing Agreement

Shares of Genetic Technologies Ltd. (NASDAQ: GENE) practically doubled in Tuesday’s session following a key licensing agreement. The company announced the signing of an exclusive worldwide license agreement with the University ...
Read Full Story »
100 dollar bills

Cotiviti Gears Up for Secondary Offering

Cotiviti Holdings Inc. (NYSE: COTV) filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. The company intends to offer 10 million shares with ...
Read Full Story »